JP2023535444A5 - - Google Patents
Info
- Publication number
- JP2023535444A5 JP2023535444A5 JP2023504622A JP2023504622A JP2023535444A5 JP 2023535444 A5 JP2023535444 A5 JP 2023535444A5 JP 2023504622 A JP2023504622 A JP 2023504622A JP 2023504622 A JP2023504622 A JP 2023504622A JP 2023535444 A5 JP2023535444 A5 JP 2023535444A5
- Authority
- JP
- Japan
- Prior art keywords
- complex according
- antibody
- oligonucleotide
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055768P | 2020-07-23 | 2020-07-23 | |
| US63/055,768 | 2020-07-23 | ||
| US202063061839P | 2020-08-06 | 2020-08-06 | |
| US63/061,839 | 2020-08-06 | ||
| US202163143828P | 2021-01-30 | 2021-01-30 | |
| US63/143,828 | 2021-01-30 | ||
| US202163181456P | 2021-04-29 | 2021-04-29 | |
| US63/181,456 | 2021-04-29 | ||
| PCT/US2021/040987 WO2022020106A1 (en) | 2020-07-23 | 2021-07-09 | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026066450A Division JP2026129755A (ja) | 2020-07-23 | 2026-04-14 | 顔面肩甲上腕型筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535444A JP2023535444A (ja) | 2023-08-17 |
| JP2023535444A5 true JP2023535444A5 (cg-RX-API-DMAC7.html) | 2024-07-11 |
| JP7851294B2 JP7851294B2 (ja) | 2026-04-24 |
Family
ID=79729849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504622A Active JP7851294B2 (ja) | 2020-07-23 | 2021-07-09 | 顔面肩甲上腕型筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230272065A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4185314A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7851294B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230046297A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116348139A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021313057A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023001003A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3186746A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299666A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023000961A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022020106A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| CN116096890A (zh) | 2020-04-02 | 2023-05-09 | 米雷楚莱股份有限公司 | 使用工程化寡核苷酸的靶向抑制 |
| AU2021313058A1 (en) * | 2020-07-23 | 2023-03-30 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| EP4185320A4 (en) * | 2020-07-23 | 2025-10-08 | Dyne Therapeutics Inc | MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2023283623A1 (en) * | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| WO2024011135A2 (en) * | 2022-07-06 | 2024-01-11 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| AU2023303022A1 (en) * | 2022-07-06 | 2025-01-02 | Dyne Therapeutics, Inc. | Cns targeting complexes and uses thereof |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
| WO2025255283A1 (en) * | 2024-06-07 | 2025-12-11 | Dyne Therapeutics, Inc. | Dosing of muscle targeting complexes for treating facioscapulohumeral muscular dystrophy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10538763B2 (en) * | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
| CA2990785C (en) * | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
| GB201512365D0 (en) * | 2015-07-15 | 2015-08-19 | King S College London | Novel therapy |
| FR3049951A1 (fr) * | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
| DK3473270T5 (da) | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
| KR20240172236A (ko) * | 2017-01-06 | 2024-12-09 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법 |
| UY38247A (es) * | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| EP3829594A4 (en) * | 2018-08-02 | 2022-05-11 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY |
| EP3830259A4 (en) * | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| CN112955154A (zh) * | 2018-08-02 | 2021-06-11 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途 |
| CN112930193A (zh) * | 2018-08-02 | 2021-06-08 | 达因疗法公司 | 肌肉靶向复合物及其在治疗肌肉萎缩中的用途 |
| IL312067B2 (en) * | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
-
2021
- 2021-07-09 CN CN202180065042.1A patent/CN116348139A/zh active Pending
- 2021-07-09 KR KR1020237005852A patent/KR20230046297A/ko active Pending
- 2021-07-09 MX MX2023000961A patent/MX2023000961A/es unknown
- 2021-07-09 BR BR112023001003A patent/BR112023001003A2/pt unknown
- 2021-07-09 WO PCT/US2021/040987 patent/WO2022020106A1/en not_active Ceased
- 2021-07-09 US US18/017,173 patent/US20230272065A1/en active Pending
- 2021-07-09 AU AU2021313057A patent/AU2021313057A1/en active Pending
- 2021-07-09 IL IL299666A patent/IL299666A/en unknown
- 2021-07-09 CA CA3186746A patent/CA3186746A1/en active Pending
- 2021-07-09 EP EP21846007.9A patent/EP4185314A4/en active Pending
- 2021-07-09 JP JP2023504622A patent/JP7851294B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532832A5 (cg-RX-API-DMAC7.html) | ||
| JP2021533200A5 (cg-RX-API-DMAC7.html) | ||
| JP2021533197A5 (cg-RX-API-DMAC7.html) | ||
| JP2024546436A5 (cg-RX-API-DMAC7.html) | ||
| JP2024525614A5 (cg-RX-API-DMAC7.html) | ||
| JP2023535078A5 (cg-RX-API-DMAC7.html) | ||
| JP2024501872A5 (cg-RX-API-DMAC7.html) | ||
| JP2021533199A5 (cg-RX-API-DMAC7.html) | ||
| JP2023512442A5 (cg-RX-API-DMAC7.html) | ||
| JP2023535074A5 (cg-RX-API-DMAC7.html) | ||
| US9163241B2 (en) | Cell-type specific aptamer-siRNA delivery system for HIV-1 therapy | |
| JP2023510351A5 (cg-RX-API-DMAC7.html) | ||
| KR101605932B1 (ko) | Hsf1-관련 질환을 치료하기 위한 유기 조성물 | |
| Wullner et al. | Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2 | |
| KR20230044242A (ko) | 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도 | |
| EP2121929B1 (en) | Targeted delivery of sirna | |
| JP2023512441A5 (cg-RX-API-DMAC7.html) | ||
| JP2008527993A (ja) | 特異性及び送達の改善のためのsiRNA分子、shRNA分子又はアンチセンス分子及び機能的実体を含む複合体 | |
| IL317871A (en) | Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy | |
| CA3209418A1 (en) | Compositions and methods for modulating pnpla3 expression | |
| CA3124664A1 (en) | Compositions and methods for inhibiting hmgb1 expression | |
| US20250290071A1 (en) | Stat3 targeting oligonucleotides and uses thereof | |
| US20250205352A1 (en) | COMPOSITIONS AND METHODS FOR MODULATING NaV1.8 | |
| AU2019213316B2 (en) | Organic compositions to treat HSF1-related diseases | |
| Prater | Antisense oligonucleotides directed to the HIV-1 Rev Response Element: Effects of nucleotide modification on oligo binding affinity, nuclease stability, and cellular uptake |